Novartis, Merck KGaA and Biogen: Which new MS drug do doctors like best? You might be surprised

While new multiple sclerosis drugs from Novartis, Merck KGaA and Biogen have hit the market this year, all bearing blockbuster hopes, one group of doctors weren't all that interested in them.

Instead, a repurposed therapy not yet approved for MS attracted “unanimous excitement,” an analyst said.

Recent MS drug entrants—Novartis’ Mayzent, Merck’s Mavenclad and Biogen’s Vumerity—only have “distinctions without differences” from existing products, five MS physicians told SVB Leerink analyst Geoffrey Porges’ team.